Cardiocity’s RhythmPad has completed another NIHR accredited clinical trial and provided an accuracy of 97% with regards comparison blinded analysis of a Gold Standard 12 lead with the RhythmPad’s 6 lead output. The trial, conducted on 752 patients, which was undertaken at St Peter’s Hospital in Chertsey, Surrey, UK concluded a sensitivity and specificity of 93% and 98% respectively.
Cardiocity’s Dr Chris Crockford said of the trial “Cardiocity’s RhythmPad remains the only clinically validated 1 and 6 lead Mass Screening device for Cardiac Arrhythmia. Hand held devices will never work on the 5% of people who are isoelectric when measured from the hands. Cardiocity’s RhythmPad was designed to enable screening of 100% of the population and as such we have now verified the performance of the system.”
An abstract was published at the 17th International Symposium on Progress in Clinical Pacing 2016, www.pacing2016.com